Hikma raises guidance on back of doxycycline shortages
This article was originally published in Scrip
Hikma has reported strong first half results ahead of analyst forecasts. Revenue increased by 20% to $638m. As a result, full year guidance has been raised to around 20% revenue growth (compared with 17% previously). Profit increased by 82% to $74m.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.